Mortalin (HSPA9) facilitates <i>BRAF</i> -mutant tumor cell survival by suppressing ANT3-mediated mitochondrial membrane permeability
Pui–Kei Wu, Seung‐Keun Hong, Wenjing Chen, Andrew Becker, Rebekah L. Gundry, Chien‐Wei Lin, Hao Shao, Jason E. Gestwicki, Jong‐In Park
Abstract
tumor cells in culture and in vivo, including their B-Raf inhibitor-resistant progenies. These findings suggest that targeting mortalin has potential as a selective therapeutic strategy in B-Raf-mutant or MEK-ERK-driven tumors.
Topics & Concepts
MutantMAPK/ERK pathwayCell biologyHeat shock proteinCellApoptosisChemistryCancer researchMembrane permeabilityBiologyGeneMembraneSignal transductionBiochemistryHeat shock proteins researchGenetics, Aging, and Longevity in Model OrganismsEndoplasmic Reticulum Stress and Disease